April 28, 2020 10:32 AM EDT

Astellas partners with Insilico, Harvard; Zambon gets FDA's fast track status for lung drug

ENDPOINTS

→ Another day, another Insilico deal. Weeks after unveiling a tie-up with Germany’s Boehringer Ingelheim — the prolific dealmaking powers-that-be at the Hong Kong-based AI …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Astellas partners with Insilico, Harvard; Zambon gets FDA's fast track status for lung drug

ENDPOINTS

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Astel­las part­ners with In­sil­i­co, Har­vard; Zam­bon gets FDA's fast track sta­tus for lung drug

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Astellas partners with Insilico, Harvard; Zambon gets FDA's fast track status for lung drug